If the findings of a new retrospective study are confirmed in a randomized controlled trial, phosphodiesterase-5 inhibitors could become standard of care in this setting.
Post-Implant PDE5 Inhibitor Therapy Lowers Thrombotic Events in LVAD Patients
An analysis of the INTERMACS registry finds that use of phosphodiesterase 5 inhibitors after LVAD placement improves survival and reduces thrombotic events, setting the stage for a randomized trial.